6533b86cfe1ef96bd12c8a62
RESEARCH PRODUCT
A variant of Smurf2 protects mice against colitis-associated colon cancer by inducing transforming growth factor β signaling.
Christoph BeckerClemens NeufertSusanne RosfaJürgen SieblerHeike DornhoffHeike DornhoffDennis StrandStefan TenzerJürgen MarklJonas MudterMarkus F. NeurathMarkus F. NeurathStefan Wirtzsubject
Colorectal cancermedicine.medical_treatmentLymphocyteUbiquitin-Protein LigasesSMADBiologyProinflammatory cytokineReceptors G-Protein-Coupledchemistry.chemical_compoundMiceTransforming Growth Factor betamedicineAnimalsCells CulturedHepatologyAzoxymethaneGene Expression ProfilingGastroenterologymedicine.diseaseColitisMolecular biologyUbiquitin ligaseMice Inbred C57BLProto-Oncogene Proteins c-kitCytokinemedicine.anatomical_structureHyaluronan ReceptorschemistryColonic Neoplasmsbiology.proteinCancer researchTransforming growth factorSignal Transductiondescription
Background & Aims Transforming growth factor (TGF)-β signaling, which is down-regulated by the E3 ubiquitin ligase Smad ubiquitin regulating factor 2 (Smurf2), promotes development of cancer. We identified a splice variant of Smurf2 (ΔE2Smurf2) and investigated its role in colon carcinogenesis in mice. Methods Colitis-associated colon cancer was induced in mice by administration of azoxymethane, followed by 3 cycles of oral administration of dextran sodium sulfate. Messenger RNA levels of Smurf2 in colon tumors and control tissue were measured by quantitative polymerase chain reaction; lymphocyte and cytokine levels were measured in tumor and tissue samples. Results Tumor-infiltrating CD4 + cells expressed higher levels of ΔE2Smurf2 than CD4 + cells from nontumor tissues of wild-type mice. T cell–specific overexpression of ΔE2Smurf2 increased TGF-β signaling by suppressing protein levels of Smurf2, accompanied by an increase in levels of TGF-β receptor type II. Transgenic mice that overexpress ΔE2Smurf2 were protected against development of colitis-associated tumors and down-regulated proinflammatory cytokines such as interleukin-6. Patients with chronic inflammatory bowel disease had a significantly lower ratio of Smurf2/ΔE2Smurf2 than control individuals. Conclusions T cell–specific ΔE2Smurf2 degrades wild-type Smurf2 and controls intestinal tumor growth in mice by up-regulating TGF-β receptor type II, reducing proliferation and production of proinflammatory cytokines.
year | journal | country | edition | language |
---|---|---|---|---|
2011-06-03 | Gastroenterology |